Classifications: immunomodulator; monoclonal antibody; immunoglobulin; Therapeutic: monoclonal antibody; immunoglobulin (igg)
Pregnancy Category: C
100 mg vial
Monoclonal antibody (IgG1k produced by recombinant DNA technology) to the respiratory syncytial virus (RSV).
Provides passive immunity against respiratory syncytial virus. Indicated by prevention of lower respiratory tract infection.
Prevention of serious lower respiratory tract infections in children susceptible to RSV.
Hypersensitivity to palivizumab; pregnancy (category C), lactation.
Hypersensitivity to other immunoglobulin preparations, blood products, or other medications; kidney or liver dysfunction;
acute RSV infection.
Route & Dosage
Child: IM 15 mg/kg qmo during RSV season
- Reconstitute solution by gently injecting 1 mL of sterile water for injection (without preservative) toward the sides of
the vial. Gently swirl for 30 sec to dissolve (do not shake solution). Allow to stand at room temperature for at least 20
min until solution clears.
- Give IM only into the anterolateral aspect of the thigh. Volumes >1 mL should be divided and given in different sites.
- Use reconstituted solution within 6 h. Discard any unused portion of the vial. It contains no preservatives.
Adverse Effects (≥1%)Body as a Whole: Otitis media,
pain, hernia. GI:
Increased AST, diarrhea
, nausea, vomiting, gastroenteritis. Respiratory: URI, rhinitis,
pharyngitis, cough, wheeze, bronchiolitis, asthma
, croup, dyspnea
, apnea. Skin: Rash.
Assessment & Drug Effects
- Lab tests: Periodic monitoring of liver functions may be warranted.
- Monitor carefully for and immediately report S&S of respiratory illness including fever, cough, wheezing, and retractions.
- Assess for and report erythema or indurations at injection site.
Patient & Family Education
- Contact physician if S&S of respiratory illness, vomiting, diarrhea, or redness develop at injection site.